News Releases

Quick-Med Technologies' CEO Goes on Record With The Wall Street Transcript

Download PDF

In-Depth Interview Discusses Company's Accomplishments, Pipeline and Outlook

GAINESVILLE, Fla., Nov. 24, 2010 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCBB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that The Wall Street Transcript (TWST) has included an interview with the Company's Chief Executive Officer, J. Ladd Greeno, in the publication's latest Pharmaceutical Report.  

In the interview, Mr. Greeno provides a detailed look at Quick-Med's three core antimicrobial technologies which include: NIMBUS® FDA-cleared wound care dressing, Stay Fresh™ textile treatment and NimbuDerm™ hand sanitizer.  Mr. Greeno also discusses the considerable strides Quick-Med has made in the past year protecting its intellectual property and brokering licensing deals with pharmaceutical, medical device and major industry players in the healthcare segment.

The entire 2,700 word interview is available on the News and Publications page of the Company's website: The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

About The Wall Street Transcript

For more than 40 years, The Wall Street Transcript has been interviewing CEOs of Public Companies, Industry Analysts, and Money Managers. It is a subscriber-based online and print publication for institutional investors and is available directly in print, at, on institutional/corporate intranets and indirectly via major databases, including First Call, Lexis-Nexis, Factiva, and Dialog. For more information, see The Wall Street Transcript Online: TWST.COM

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the consumer and healthcare markets. The Company is developing advanced antimicrobial technologies for infection prevention and control. Its NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial available in a wound dressing. Its NimbuDerm™ technology is being developed as a persistent hand sanitizer and its new Stay Fresh™ technology provides highly durable antimicrobial protection for apparel and other textile applications. For more information, see:

© 2010 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® is a registered trademark and Stay Fresh™ and NimbuDerm™ are trademarks of Quick-Med Technologies, Inc.

The Quick-Med Technologies, Inc. logo is available at

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at

CONTACT:  Quick-Med Technologies
J. Ladd Greeno, CEO
(888) 835.2211 Ext 102

The Ruth Group
Eric Reiss (media)
(646) 536-7032
Ashleigh Barreto (investors)
(646) 536-7028

company logo

Source: Quick-Med Technologies, Inc.